You are here

Bone Metastases: recommendations and survival

By Robert Coleman, recorded at TAO (Transatlantic Oncology meeting), Nov 20-21, 2014, Paris

14- Robert Coleman ANG

Supportive care measures can sometimes change the outcome of the underlying disease; one such example is the notion of bone protection which is quite important in modifying the metastatic process as the bone marrow microenvironment plays a central role in tumour dormancy and metastasis. Robert Coleman speaks about the use of bone protection in its classic sense, i.e. to prevent cancer treatment-induced bone loss, as well as the manipulation of the bone microenvironment by bone-targeted drugs. Bisphosphonates are a class of drugs used to treat hypercalcemia and prevent skeletal morbidity; however, adjuvant bisphosphonates also reduce bone metastases and improve survival. Robert Coleman presents data of recent meta-analyses which suggest that patients should receive bisphosphonates not only for their bone protection, but also for their anti-cancer effects.


Robert Coleman, University of Sheffield, UK

Search this site

Featured videos

Free access to ebooks on cachexia and CINV


Prevention of nausea and vomiting in
adult cancer patients receiving tumour-
directed therapy – 2017 update –

Cancer cachexia: mechanisms and progress in treatment


Stay up-to-date with our monthly e-alert

If you want to regularly receive information on what is happening in Quality of Life in Oncology research sign up to our e-alert.

Subscribe »

QOL (Quality of Life) newsletter e-alert

Quality of Life promotional video

Made possible by an educational grant from Helsinn

Helsinn does not have any influence on the content and all items are subject to independent peer and editorial review

Society Partners

European Cancer Organisation Logo